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Inflammatory states seen in infection and chronic disorders are often 
characterized by a condition called anemia of inflammation (AI). The iron 
deficiency in AI is predominantly due to an altered balance of the cytokine, 
Interleukin-6 (IL6) and the hormone hepcidin (Hamp). We have previously shown 
that lack of IL6 or Hamp in knockout mouse models (IL6-KO, Hamp-KO) injected 
with the heat-killed pathogen Brucella abortus (BA) results in improved recovery 
from anemia. However, BM erythroid recovery in IL6-KO mice was far more 
improved in comparison to the iron overloaded Hamp-KO mice. This prompted us 
to investigate cellular responses driving BM erythropoiesis under inflammation in 
IL6-KO mice and the effect of iron overloading conditions on erythroid recovery 
under condition of AI. To address these questions, we generated a double knock 
out for IL6 and Hamp (DKO) and investigated BM erythropoiesis in WT, IL6-KO, 
Hamp-KO and DKO mice. 
The erythroid recovery in the BM of these mice were characterized by two 
phases. During the first phase (in the first 72 hours following BA administration), 
all the mice showed impaired BM erythropoiesis. Analysis of WT and IL6-KO 
mice indicated that impaired BM was associated by a surge in inflammatory 
cytokines such as IFNg and TNFa and a concurrent increase in mitochondrial 
ROS. Following 72 hours BM erythropoiesis recovered in the BM: compared to 
WT and Hamp-KO, BM erythropoiesis was qualitatively and quantitatively better 
in IL6-KO animals, showing the best profile in DKO mice. During the second 
phase (10 to 14-day post BA administration), we observed a second surge of 
inflammatory cytokines. During this phase, we observed a severe regression of 
BM erythropoiesis in DKO mice, while IL6-KO animals continued to show an 
excellent profile.  
During the second phase, we also observed that, while WT mice 
upregulated mitochondrial ROS, IL6-KO animals did not. We showed that ROS 
upregulation is triggered by erythropoietic stress (as seen in WT animals 
recovering after phlebotomy). However, we also postulated that inflammation and 
iron overload can further increase oxidative stress in erythroid cells, and that 
excessive ROS upregulation impairs erythroid recovery. Hence, BM 
erythropoiesis in IL6-KO mice is improved by reduced ROS formation in 
presence of inflammatory cytokines. However, if our model is correct, 
administration of iron to IL6-KO animals should impair BM erythropoiesis during 
the second phase as seen in DKO. In fact, iron administration impaired BM 
erythropoiesis in IL6-KO mice and, concurrently, increased ROS in erythroid 
cells. In accordance with our model, during the second phase also DKO and 
Hamp-KO mice showed increased ROS in BM erythroid cells. We are currently 
investigating which form of iron is responsible for this mechanism (labile iron pool 
versus transferrin bound iron) and what  the role of IL6 is in this process. 
	 iv	
 
BIOGRAPHICAL SKETCH 
Ritama received her Bachelor of Science in Microbiology from St. Xavier’s 
college, University of Calcutta, at Kolkata, India. She joined the PhD program in 
Immunology and Microbial Pathogenesis at Weill Cornell Graduate School of 
Medical Sciences in the fall of 2011 and subsequently started work in the Rivella 
lab on erythropoietic disorders. She currently works as an in abstentia graduate 
student with Dr. Stefano Rivella at the University of Pennsylvania and The 
Children's Hospital of Philadelphia; investigating the role of Interleukin 6 and 
Hepcidin in a mouse model of anemia of inflammation. 
 
 
 
 
 
 
 
 
 
 
 
 
	 v	
DEDICATION 
This doctoral dissertation is dedicated to my late grandmother Smt. Gauri Gupta. 
This PhD would not have been possible without her constant support of my 
educational goals and I know she would be proud of me today. 
I would like to thank my parents Raja Gupta and Rajashi Gupta, who have 
worked tirelessly and made innumerable sacrifices throughout their lives to help 
me get to where I am today. Thank you for teaching me the strength of humility, 
hard work, discipline, and perseverance.  
I would like to share this PhD with my brother Dot- my friend, my helping hand, 
my confidant for life. Thank you for having faith in me, when I didn’t have faith in 
myself. 
I am also grateful for my childhood best friend Maddy-our friendship has survived 
the test of time and distance, and I know I would not have been able to begin and 
complete this chapter of my life without your support. 
My utmost gratitude to my PhD mentor Dr. Stefano Rivella. Your kindness on one 
hand and positive criticism on the other, have made this PhD possible. It has 
been an honor to learn and work under your guidance.  
Thank you to my graduate school best friends-Alisa and Dane. Right from the 
beginning, we have carried each other, through hurdles both professional and 
personal. Some of my most cherished moments in graduate school have you two 
in it, and I will carry them with me for the rest of my life. 
Roberta, your scientific assistance has been instrumental in bringing my PhD 
thesis to completion, thank you for that, and also for your friendship that has 
shaped my life in lab. Truly, my time in lab has been infinitely brighter in your 
presence. Thank you to Carla, for teaching me everything about mouse work, I 
owe my skill and knowledge of handling animals to your guidance. I am also 
indebted to Sara, for introducing this project to me, and for her elegant work on 
the Brucella model that has been the foundation of my project. Every past and 
previous member of my lab that I have had the pleasure of working with has 
contributed to this PhD, and I am very grateful for it. 
I would also like to extend my gratitude to my first teacher in Immunology, Kasturi 
Ma’am and the head of the department of Microbiology at my alma mater St. 
Xavier’s College, Kolkata-AKM sir. Your lessons inspired me to pursue scientific 
	 vi	
research. Some of the most inspiring figures in my life in India have been 
teachers. But none have inspired me as much as you have, Riddhi sir. Thank you 
for your kindness, and support. I felt the first shadow of having a professional 
mentor in you and in our conversations at St. Xavier’s. 
Last but not the least, I would like to thank my fur friend and baby Lavender. You 
came into my life at a time when I needed a friend the most and you have 
captured my heart with your undying love. I know that this milestone in my life 
has been made ever so special by your presence. 
Thank you to every person, stranger, family or friend; whose random acts of 
kindness have helped me push through the past six years and bring this chapter 
of my life to completion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 vii	
 
 
ACKNOWLEDGEMENT 
 
This work was supported by funding from the National Institute of Health (NIH). 
The authors gratefully acknowledge the insightful inputs of Dr. Douglas Wallace 
at the Children’s Hospital of Philadelphia and Dr. Nilam Mangalmurti at the 
University of Pennsylvania. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 viii	
 
 
TABLE OF CONTENTS 
 
 
 
 
 
 
Title Page i 
Copyright Page ii 
Abstract iii 
Biographical Sketch iv 
Dedication v-vi 
Acknowledgements vii 
Table of Contents viii 
List of Figures ix-x 
List of Abbreviations xi-xii 
Chapter One. Introduction 1-32 
Chapter Two. Results 33-51 
Chapter Three. Methods 52-56 
Chapter Four. Discussion and Future Perspectives 57-60 
Chapter Five. References 61-80 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 ix	
 
LIST OF FIGURES 
 
 
 
 
 
Chapter One 
 
Figure 1.1. Terminal erythroid differentiation resolved by expression 
of TER119, CD71 and CD44.   
4 
Figure 1.2. Cellular iron homeostasis. 7 
Figure 1.3. Role of Hepcidin in negative regulation of iron availability. 8 
Figure 1.4. Generation of superoxide anion (O2.-) within the 
mitochondrial ETC. 
17 
Figure 1.5. ROS and opening of mitochondrial permeability transition 
pore. 
19 
Figure 1.6. Intrinsic cellular processes triggered in response to 
cellular injury. 
23 
Figure 1.7. IL6 activation stimulates the Hepcidin promoter. 26 
Figure 1.8. Hallmarks of IRE induced by changes in iron homeostasis 
under inflammation. 
27 
Figure 1.9. IL6 KO mice show improved BM erythropoiesis under AI. 32 
 
 
 
 
 
Chapter Two 
 
Figure 2.1. Both iron overloaded models of Hamp- KO and the DKO 
show similar recovery of peripheral blood hemoglobin levels under AI. 
34 
Figure 2.2. The DKO displays a biphasic trend in peripheral blood cell 
count. 
35 
Figure 2.3. Two weeks following inflammatory insult, the IL6-KO 
shows the most improved Bone Marrow (BM) erythroid recovery with 
a concurrent regression in the same of the DKO. 
37 
Figure 2.4. Quantification of progenitor cell numbers in the BM 
confirm improved erythroid recovery of the IL6-KO. 
38 
Figure 2.5. The spleen shows no significant difference in extra 
medullary erythropoiesis, between the Hamp-KO, IL6-KO and the 
DKO. 
39 
Figure 2.6. Pattern of BM erythroid recovery in the different 
genotypes reveals two major phases of divergence, phase one and 
phase two. 
40 
Figure 2.7. During phase one of recovery under inflammation, 
mitochondrial superoxide levels within BM erythroid progenitors 
increase in both the WT and the IL6-KO. 
42 
	 x	
Figure 2.8. In phase one of recovery under inflammation, both WT 
and IL6-KO upregulate serum cytokines. 
43 
Figure 2.9. During phase two of recovery under inflammation, 
mitochondrial superoxide levels within BM erythroid progenitors 
increase in the WT but not in the IL6-KO. 
44 
Figure 2.10. During phase two of recovery under inflammation, 
cytoplasmic ROS levels within BM erythroid progenitors increase in 
the WT but not in the IL6-KO. 
45 
Figure 2.11. During phase two of recovery under inflammation, the 
spleen is protected from ROS upregulation. 
46 
Figure 2.12. ROS upregulation is a physiological by-product of stress 
erythropoiesis, but becomes detrimental in the presence of iron 
overload. 
48 
Figure 2.13. The spleen is protected from ROS upregulation under 
conditions of iron overload. 
49 
Figure 2.14. During phase two of recovery under inflammation, the 
WT shows presence of iron in the serum not bound to transferrin. 
50 
Figure 2.15. A model of erythroid recovery under AI. 51 
 
 
 
 
 
Chapter Three, Chapter Four and Chapter Five: None 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 xi	
 
 
LIST OF ABBREVIATIONS 
 
 
 
 
 
AI Anemia of Inflammation 
AP-2 Adaptor Protein -2 
ADP Adenosine Di Phosphate 
atg8 autophagy related protein 8 
ATP Adenosine Tri Phosphate 
BA Brucella abortus 
BFU-E Burst Forming Unit- Erythroid 
BM Bone Marrow 
BMP Bone Morphogenic Protein 
CEBP-a CCAAT Enhancer binding protein a 
CFU-E Colony Forming Unit-Erythroid 
CFA Complete Freud’s Adjuvant 
CHOP CEBP Homologous protein 
CLP Cecal Ligation and Puncture 
DAMP Damage associated Molecular Pattern 
Dcytb Duodenal cytochrome b 
DMT1 Divalent Metal ion Transporter 
DNA Deoxyribonucleic Acid 
ER Endoplasmic Reticulum 
ETC Electron Transport Chain 
G-csf Granulocyte-colony stimulating factor 
gp80 glycophorin 80 
Hamp-KO Hepcidin-knock out 
HFE High Fe hemochromatosis protein 
HIF Hypoxia inducible factor 
HIV Human Immunodeficiency Virus 
HSC Hematopoietic Stem Cell 
IFNg Interferon g 
IL6 Interleukin 6 
IL6-KO Interleukin 6- knock out 
IP Intraperitoneal 
IRE Iron Restricted Erythropoiesis 
JAK Janus Kinase 
KEAP1 Kelch like ECH Associated Protein-1 
LC3 Microtubule associated Light Chain 3 
MAPK Mitogen Associated Protein Kinase 
M-csf Monocyte-colony stimulating factor 
	 xii	
MLKL Mixed Lineage Kinase Domain Like Pseudokinase 
mPTP Mitochondrial Permeability transition pore 
mRNA Messenger Ribonucleic Acid 
NADH Nicotinamide Adenine Dinucleotide reduced 
NFkB Nuclear Factor kB 
NLR Nod Like Receptor 
NLRP3 NLR family Pyrin domain containing 3 
Nramp-1 Natural resistance associated macrophage protein-1 
NRF2 Nuclear factor erythroid 2 related Factor 2 
NTBI Non-Transferrin Bound Iron 
PAMP Pathogen Associated molecular pattern 
RBC Red Blood Cell 
RIPK1 Receptor Interacting Serine/Threonine kinase 1 
RNA Ribonucleic Acid 
ROS Reactive Oxygen Species 
SOD1 Superoxide Dismutase 1 
STAT3 Signal Transducer and Activator of Transcription 3 
Tf Transferrin 
TfR1 Transferrin Receptor 1 
TGFb Transforming growth factor b 
TLR Toll like receptor 
TMPRSS6 Transmembrane Protease Serine 6 
TNFa Tumor necrosis factor a 
TNFR Tumor necrosis factor a Receptor 
TRAF2 TNF Receptor Associated Factor 2 
WT Wild Type 
ZIP8 Zrt and Irt like Protein 8 
	 1	
 
Chapter One 
Introduction 
Erythrocytes are the primary carrier of oxygen in vertebrate systems. They 
are generated from multipotent HSCs mostly in the bone marrow of adult 
vertebrates by a process known as Hematopoiesis. Oxygen carrying capacity of 
erythrocytes stems from their key constituent Heme, capable of binding to iron 
and delivering oxygen to tissue through circulating RBCs. As a result, 
erythropoiesis and iron levels are tightly linked in mammalian systems in order to 
maintain a healthy balance of iron utilization for generation of new erythroblasts 
and iron recycling from senescent erythrocytes. 
       Iron has some unique properties that  makes  it  crucial to the 
functioning of the mammalian physiological system. One such property is its 
interconversion from ferric (Fe3+) to ferrous (Fe2+) form (1). While this makes iron 
an essential component of oxygen carrying proteins like Hemoglobin and 
Myoglobin, as well as many redox enzymes, it also allows iron to generate 
harmful oxidative radicals (2). This dichotomous nature of Iron functioning 
requires this element to be tightly regulated. A careful balance of iron absorption 
and iron discharge is maintained in mammals, to simultaneously utilize iron for 
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physiological benefits and circumvent its potentially harmful properties. Loss of 
this balance is the underlying cause of many disorders, with symptoms ranging 
from anemia to hemochromatosis (iron overload). Although many of these 
disorders have been identified and some characterized, their underlying 
molecular mechanisms have only recently begun to be elucidated. 
     AI, also known as anemia of chronic diseases, is believed to be the 
second most common cause of anemia after iron deficiency anemia (3). It affects 
patients with both acute and chronic inflammation, seen in infections, 
malignancies and autoimmune disorders (4, 5, 6). A substantial proportion of 
patients suffering from acute or chronic infections are affected by AI. These 
infections include HIV, hepatitis C virus, diseases like tuberculosis, and others (7, 
8, 9). Along with infections, cancer patients also exhibit symptoms of AI. Within 
autoimmune disorders, AI can affect patients with rheumatoid arthritis, 
inflammatory bowel disorder and systemic lupus erythematous (5, 10, 11). AI has 
also been reported in cases of chronic kidney disease, cardiovascular disease 
and in patients with rejection following an organ transplant (12, 13, 14). While in 
the case of acute AI, prognosis is directly linked to clearance of the pathogen 
from the body, in chronic AI, symptoms worsen with disease progression, thereby 
affecting treatment and management options. Therapies geared towards treating 
the anemia with iron supplements are not only ineffective in some cases, but can 
also be detrimental when iron allows the pathogen to thrive, as is the case in 
many infections (15). Thus, understanding the cellular mechanisms of 
	 3	
dysregulated iron metabolism, which contribute to AI, is critical for designing 
effective cures 
 
Erythroid differentiation and generation of RBCs 
Erythropoiesis 
Erythropoiesis is the process in which HSCs proliferate and differentiate to 
generate enucleate erythrocytes or RBCs. It occurs in two phases: proliferation of 
erythroid progenitors and terminal erythroid differentiation. In the first phase of 
erythroid progenitor proliferation, multipotent HSCs will proliferate and 
differentiation into BFU-E which in turn gives rise to CFU-E (16). Terminal 
erythroid differentiation starts at the pro-erythroblast stage. This stage undergoes 
three consecutive mitosis to generate basophilic erythroblast followed by 
polychromatic erythroblast and then orthochromatic erythroblasts. Generally, one 
pro-erythroblast gives rise to 2 basophilic erythroblasts, these 2 basophilic 
erythroblasts will create 4 polychromatic erythroblasts and then the latter 
undergoes further mitosis to give 8 orthochromatic erythroblasts thereby 
maintaining a 1: 2: 4: 8 ratio from the pro-erythroblast to the orthochromatic 
erythroblast stage (17). The othorchromatics expel their nuclei to generate 
reticulocytes which undergo further changes to give rise to erythrocytes or RBCs. 
Terminal erythroid differentiation is accompanied by a decrease in expression of 
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certain cell surface proteins, decrease in cell size, changes in organization of 
membrane structure, chromatin condensation and hemoglobinization during the 
transition from the pro-erythroblast to the RBC stage (17). 
Characterization of progenitor populations in terminal erythroid 
differentiation 
The two major sites of erythropoiesis in adult mammals are the BM and 
the spleen. Terminal erythroid differentiation in the murine BM and spleen has 
been extensively characterized by distinguishing individual progenitor 
populations by expression of cell surface makers using flow cytometry, 
morphological features by cytospins and genetic characteristics by RNA 
sequencing (17, 18). The most widely accepted and adaptable method of 
identifying erythroid progenitor populations is by using the cell surface erythroid 
marker TER119. Cells expressing TER119 can be distinguished into each 
progenitor population by difference in expression of CD44. Beginning from the 
pro erythroblast stage each subsequent population undergoes a decrease in 
expression of CD44 and shrinks in size to give rise to RBCs (Figure 1). Another 
marker used in identifying progenitor populations is CD71. Early in terminal 
erythroid differentiation erythroid progenitors are TER119+CD71+ while RBCs are 
TER119+CD71- (Figure 1). 
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Figure 1.1. Terminal erythroid differentiation resolved by expression of 
TER119, CD71 and CD44.  (I) Pro-erythroblast, (II) Basophilic erythroblast (III) 
Polychromatic erythroblasts (IV) Orthochromatic erythrobalst and reticulocyte (V) 
RBCs. Adapted and modified from Chen et al.  
           Iron metabolism and its regulation 
Iron homeostasis 
       The majority of iron in the mammalian body is located in hemoglobin, 
which is the predominant protein in erythrocytes (or RBCs). Plasma also contains 
iron, where it is maintained in the soluble form by binding to the glycoprotein Tf, 
which supplies it to cells like developing erythrocytes, hepatocytes and placental 
trophoblasts by binding to the transmembrane Tf receptor on the cell surface (19, 
20, 21, 22). The level of Tf saturation can in certain cases be used as an 
indicator of iron deficiency or iron overload. Very low Tf saturation implies iron 
deficiency, while excessive saturation of Tf signals iron overload. When the 
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amount of iron present exceeds the amount of Tf available for binding, which 
occurs in cases of exceedingly high Tf saturation (23). It gives rise to NTBI, 
which can cause oxidative damage to cells (24, 25).  A component of this NTBI 
forms the labile plasma iron which constitutes the labile iron pool within the 
plasma (26).  Although the labile iron pool consists of chelatable redox active 
iron, when tightly regulated and maintained at low levels this serves a 
homeostatic role in iron metabolism. However, in conditions of iron overload, 
dysregulated expansion of the labile iron pool causes labile plasma iron to enter 
into cells and tissues, causing damage through oxidative stress (27, 28). There 
are certain metal ion transporters such as ZIP8 implicated in iron transport (29). 
This transporter could potentially be capable of taking up this excess iron within a 
labile iron pool, not bound to transferrin-for supply to erythroid progenitors, 
subsequently extending the arm of NTBI mediated oxidative damage to erythroid 
differentiation. Whether conditions of NTBI are accompanied by dysregulated 
expression of ZIP transporters remains to be seen.  
       Majority of this Tf bound plasma iron comes from daily recycling of 
senescent erythrocytes with the hemoglobin/haptoglobin scavenger receptor 
(CD163) (30). A small fraction of this is also derived from dietary iron. In 
duodenal enterocytes lining the absorptive villi, dietary iron is taken up in the 
ferric form with the help of a transporter called DMT1 and the enzyme ferric 
reductase, or Dcytb which reduces it to the ferrous form for cellular uptake (31, 
32). Plasma iron levels are also maintained through iron recycling by 
macrophages that phagocytose dying or senescent erythrocytes, extract iron 
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from the hemoglobin by catabolizing Heme via the hemoxygenase enzyme, and 
release it into circulation (33, 34). Release of stored iron from hepatocytes and 
placental transport of iron from the mother to the fetus also contribute to Tf bound 
plasma iron levels. Although there are multiple ways to import iron, cellular iron 
export occurs through the only known iron exporter-ferroportin wherein enzymes 
like ceruloplasmin or hephaestin oxidize the ferrous iron to ferric form following 
Ferroportin mediated export and preceding plasma Tf loading (35, 36, 37, 38) 
(Figure 2). 
 
 
Figure 1.2. Cellular iron homeostasis. Adapted from Hentze et al. 
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Ferroportin is highly expressed on the cell membrane of hepatocytes, 
macrophages, duodenal enterocytes and placental trophoblasts. 
Hepcidin 
Hepcidin is considered a key regulatory molecule of systemic iron 
homeostasis. This 25 amino acid peptide hormone is produced primarily by 
hepatocytes (39, 40). Hepcidin acts as a negative regulator of iron availability by 
preventing export of iron absorbed by duodenal enterocytes, stored iron from 
hepatocytes, recycled iron from phagocytizing macrophages and transported iron 
on placental trophoblasts. This produces immediate hypoferremia as evidenced 
by studies where a single dose of 50 ug of Hepcidin in mice caused a rapid drop 
in serum iron in 1 hour (41). Hepcidin carries out this negative regulation of iron 
availability by directly binding to the iron exporter ferroportin. This binding elicits 
internalization of the hepcidin-ferroportin complex and its consequent 
ubiquitylation and degradation in lysosomes (42, 43, 44). In a feedback loop, 
Hepcidin in itself is also regulated by the element it controls: iron. This happens 
such that when iron levels are plentiful, Hepcidin expression is upregulated. 
Circulating hepcidin binds and degrades ferroportin on the basolateral side of 
duodenal enterocytes thereby preventing release of absorbed iron into plasma. It 
also concurrently degrades Ferroportin on Macrophages and hepatocytes further 
lowering plasma iron supply (Figure 3). Conversely, under conditions of iron 
deficiency, Hepcidin expression is downregulated, releasing iron into circulation 
thereby increasing Tf saturation and plasma iron levels (45, 46, 47, 48). 
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Figure 1.3. Role of Hepcidin in negative regulation of iron availability. 
Adapted and modified from Nemeth et al. 
There are multiple factors that regulate expression of Hepcidin in the 
mammalian physiological system. One such factor is iron availability. This is 
mediated by the membrane protein HFE. Under conditions of high serum iron 
and Tf-saturation, the membrane protein HFE, generally sequestered away by 
binding to TfR1 (Transferrin receptor 1) is displaced to TfR2 (Transferrin receptor 
2) thereby forming an Fe-Tf, HFE, TfR2 complex. This complex has been 
implicated in upregulating transcription of Hepcidin (49, 50, 51). It can do so 
independently or in concert with the BMP-SMAD pathway, the key pathway in 
inducing expression of Hepcidin. BMP6, belonging to the TGFb superfamily of 
proteins binds to the BMP receptor I and II complex including the BMP 
coreceptor Hemojuvelin which confers sensitivity of binding. Activation of the 
BMP receptor leads to phosphorylation of SMAD1/5/8 in the cytosol and the latter 
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then goes on to interact and form a complex with SMAD 4 which translocates to 
the nucleus and induces expression of Hepcidin (52, 53, 54, 55). A serine 
protease Matriptase -2 encoded by the TMPRSS6 gene is capable of cleaving 
the BMP coreceptor Hemojuvelin, negatively regulating expression of Hepcidin 
such that TMPRSS6-/- mice have severe iron deficiency anemia (56, 57, 58). On 
the other side of the spectrum, mutations in gene contributing to Hepcidin 
expression, such as HFE, TfR2 and those within Hepcidin itself, can lead to 
conditions of iron overload, and are the central causes of hereditary 
hemochromatosis in clinical settings (47, 49). 
Another factor controlling Hepcidin expression is Hypoxia and 
erythropoietic activity (59). It has been shown in vitro that HIF1 and HIF2 
downregulates Hepcidin expression via upregulation of erythropoietin (60,). In 
vivo, it has been shown that stimulating erythropoiesis either by treatment with 
Erythropoietin or by phlebotomy to cause rapid anemia triggers an expansion of 
erythroid progenitors and a concurrent downregulation of Hepcidin expression 
(61). Since erythroid progenitors are the primary consumers of plasma iron, to 
prevent depletion of plasma iron levels under conditions when expansion of the 
erythroid progenitor pool is necessary, e.g. stress or ineffective erythropoiesis, 
erythropoietin treatment etc., these erythroid progenitors produce an erythroid 
factor named “Erythroferrone” which suppresses hepcidin expression. How 
erythroferrone acts on hepatocytes to suppress hepcidin remains to be 
elucidated. Upregulation of this factor is the primary cause of iron overload seen 
in genetic disorders of secondary hemochromatosis manifesting ineffective 
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erythropoiesis, such as b thalassemia (61, 62, 63). 
       The final factor that controls Hepcidin expression is inflammation. In 
acute, as well as in chronic inflammatory conditions, infections, autoimmune 
disorders, or malignancies, hypoferremia associated with upregulated Hepcidin 
expression has been observed. The most important cause of this is the 
production and upregulation of cytokines such as IL1 and IL6, which have been 
implicated in the increase of Hepcidin levels. Aside from pro inflammatory 
cytokines, ER stress has also been linked to upregulated Hepcidin levels (64, 
65). 
Inflammation 
The general inflammatory reaction 
Inflammation is considered to be an adaptive biological reaction to a 
disruption in tissue homeostasis (66). The primary aim of inflammation is in 
resolution of damage, and hence beneficial, for example, in the context of an 
infection. However, dysregulated inflammation can be injurious, for example, in 
autoimmune disorders. The general inflammatory pathway follows a sequence of 
inducers, sensors, mediators and effectors (66). Primary exogenous microbial 
inducers of inflammation include PAMPs expressed by a multitude of receptors 
on cells participating in the inflammatory response. Endogenous inducers include 
DAMPs released by previously infected cells that can further progress the 
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inflammatory reaction (67, 68). The first responding cells at the site of entry of a 
pathogen or damage to tissue, are part of the innate response. These include 
macrophages, neutrophils and mast cells that express PAMP and DAMP 
recognizing receptors such as NLRs and TLRs, which are the sensors (69, 70, 
71, 72). Activation of these receptors, the latter in particular, can trigger the rapid 
activation of the transcription factor NFkB which then translocates to the nucleus 
and induces expression of target genes (73, 74). This includes a variety of 
chemokines, cytokines, eicosanoids, vasoactive amines etc., also known as the 
mediators (66). These form the very first phase of response at the site of 
damage. Additionally, chemokines generated also allow further extravasation of 
leukocytes to the site of infection (75, 76). Depending on the degree and intensity 
of damage, the inflammation maybe be resolved by this initial response, or may 
be continued by further infiltration of macrophages, and adaptive immune cells. 
When the initial responders are capable of limiting the damage, a resolution 
phase ensues through clearance of debris and dead cells, transition from the pro-
inflammatory state to an anti-inflammatory state and replacing the area of 
damage by tissue remodeling (77). 
IL6 
IL6, though initially considered as a pro-inflammatory cytokine, has been 
shown to have pleiotropic functions regulating a multitude of cellular processes 
(78). On binding to the IL6 receptor (gp80) associated with the signal transducer 
(gp 130) it can induce the phosphorylation and activation of the transcription 
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factor STAT3 which translocates to the nucleus and stimulate expression of 
target genes (79, 80). IL6 is produced by all cells of the mononuclear phagocytic 
system, as well as by adaptive immune cells. Aside from its role in the initial 
response to invading pathogens and tissue damage during acute inflammatory 
reactions, this cytokine has been implicated in differentiation of multiple T helper 
cell subsets, in acute phase response by inducing expression of acute phase 
proteins, in osteoblast maturation, in hematopoiesis within the bone marrow and 
in inducing anemia under inflammation, among others (81, 82, 83, 84). 
TNFa 
TNFa is a key inflammatory mediator present both as a soluble and 
membrane bound form and capable of binding to TNF receptor 1 and 2. On 
binding, the latter is cleaved by membrane metalloproteinases into an activated 
form. The activated receptors can trigger downstream signaling pathways 
through TRAF2 to induce activation of AP-2 and NFkB among other factors that 
are able to upregulate the expression of multiple inflammatory mediators 
including TNFa itself (85, 86). This cytokine is primarily expressed by 
macrophages, but can also be secreted by other cells of both innate and 
adaptive immune responses. Apart from its role as an inflammatory mediator, an 
important function of TNFa is inducing expression of chemokines that allow 
extravasation of mononuclear phagoyctes, from blood vessels to the site of 
tissue damage or infection as first responders to an inflammatory reaction (87). In 
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addition to this, TNFa has also been linked to caspase-8 mediated apoptosis, 
non-apoptotic programmed cell death such as necroptosis, lipid metabolism, 
differentiation of T helper cell subsets and in maintenance of endothelial cell 
function (88, 89, 90, 91). 
IFNg 
Expression of many inflammatory mediators, including the two mentioned 
above, is regulated by IFNg. This cytokine is capable of priming macrophages 
either synergistically with activated TLRs to stimulate NFkB activation or 
independently through the phosphorylation and activation of STAT1(92). IFNg 
primed macrophages upregulate expression of over 200 genes including G-Csf, 
M-Csf and IL12-p40. INFg has also been implicated in inhibiting the expression of 
IL10, and can, in certain cases, contribute to exaggerated chronic inflammatory 
conditions such as inflammatory bowel disease and lupus (93, 94, 95). 
Mitochondria, oxidative stress and cell death 
Mitochondria 
Health and survival of a mammalian cellular system requires the 
coordinated functioning of its intracellular organelles to recognize external cues 
and respond appropriately. Mitochondria are double membrane bound 
endosymbiotic organelles capable of acting as the ultimate “responsive sensing 
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system” by detecting alterations and functioning accordingly (96). Although the 
classical function of energy homeostasis has caused these organelles to be aptly 
named as the “powerhouse of the cell”, mitochondria have also been implicated 
in a host of other functions, including but not limited to inter-organelle signaling, 
responding to cytokine cues, calcium homeostasis, activation of the 
inflammasome, generation of ROS and cell death (96). 
Mitochondria consists of two functionally distinct outer and inner 
membranes separated by an inter membrane space and encapsulating the 
mitochondrial matrix, housing among various other factors, a circular 
mitochondrial DNA encoding certain components of the ETC (97). Sensing of 
metabolites such as glucose and fatty acids results in subsequent oxidative 
phosphorylation which converges on the ETC to generate an electrochemical 
gradient across the inner mitochondrial membrane, energy in the form of ATP, 
water and ROS. Multiple megacomplexes of iron-sulfur clusters comprise the 
ETC which consists of complex I (NADH dehydrogenase), ubiquinone, complex II 
(succinate dehydrogenase), complex III (bc1 complex), cytochrome c, complex IV 
(cytochrome c oxidase) and ATP synthase. Electron transfer along the ETC is 
initiated when pyruvate generated from Glucose by Glycolysis is converted to 
Acetyl CoA in the Mitochondria by Pyruvate Dehydrogenase. Acetyl CoA is also 
produced from b-oxidation of Fatty Acids. Metabolite derived Acetyl CoA enters 
into the Krebs Cycle to produce electron donors like NADH accepted by complex 
I of the ETC to initiate transfer of electrons (98, 99, 100, 101). As electrons flow 
down the ETC, this gradient of electrons pumps protons or hydrogen ions from 
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the mitochondrial matrix across the inner mitochondrial membrane, giving rise to 
an electrochemical gradient across the membrane called mitochondrial 
membrane potential (Dym) (102). Subsequently these protons re-enter the 
mitochondrial matrix through the ATP synthase to form water while the ATP 
synthase itself utilizes the proton gradient to give rise to ATP from ADP and 
inorganic phosphate such that 36 ATP molecules are produced per molecule of 
glucose that is metabolized. Although majority of the electrons flow down the 
ETC and are involved in the generation of ATP, a few electrons are leaked and 
can react with oxygen at certain complexes of the ETC itself to generate 
oxidative radicals or ROS (103, 104). 
ROS and oxidative stress 
A small fraction of electrons moving down the ETC can generate ROS by 
the one electron reduction of oxygen at complexes of the ETC. ROS refers to 
non-radical oxidants such as hydrogen peroxide (H2O2) and singlet oxygen (1O2) 
as well as free radicals such as superoxide anion (O2.-) and hydroxyl radical 
(.OH) (105, 106, 107, 108). Incomplete reduction of molecular oxygen at 
complexes I and III gives rise to the most abundant form of ROS called 
superoxide anion (O2.-) on the mitochondrial matrix side of the inner 
mitochondrial membrane (Figure 4). The steady state concentration of the 
superoxide anion (O2.-) is about 5-10 fold higher within the mitochondrial matrix 
than it is in the cytosol or other organelles (109, 110, 111). These levels of 
superoxide anion (O2.-) which can otherwise damage iron sulfur clusters within 
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complexes of the ETC, are tightly regulated by the presence of enzymes such as 
SOD1 residing in the mitochondrial intermembrane space and SOD2 residing in 
the mitochondrial matrix (112). For this reason, high levels of superoxide anion 
(O2.-) are generally related to a decline in mitochondrial health than with steady 
state redox signaling. Mitochondrial respiration is the primary source of ROS 
because the Superoxide anion (O2.-) is capable of generating most other forms of 
ROS. Spontaneous or enzymatic dismutation of superoxide anion (O2.-) gives rise 
to hydrogen peroxide (H2O2) (Figure 4). The latter in turn can react with 
Superoxide anion (O2.-) through ferrous ion catalyzed Fenton reaction as well as 
the Haber Weiss reaction to generate the most aggressive oxidant, the hydroxyl 
radical (.OH) (113, 114, 115, 116). This potent form of ROS is capable of 
indiscriminately oxidizing proteins, lipids and DNA contributing to genomic 
instability and ultimately cell death. For this reason, there are elegant scavenging 
systems in place to maintain ROS at low levels (117). While all of these forms of 
ROS have varying degrees of reactivity, under physiological conditions ROS 
production constitutes a very small proportion of mitochondrial oxygen 
consumption, and as mentioned, is tightly regulated. 
	 18	
 
Figure 1.4. Generation of superoxide anion (O2.-) within the mitochondrial 
ETC. Adapted and modified from Zorov et al. 
Oxidative stress is triggered due to an imbalance in the formation of ROS 
and the subsequent scavenging of ROS. When the amount of ROS generated 
exceeds the amount of ROS detoxified by intracellular anti-oxidants, the cell 
enters a state of oxidative stress (118). This can occur either due to a 
dysregulated production of ROS at the mitochondrial ETC or defects in the 
function of ROS scavenging enzymes within the cytosol and/or the mitochondrial 
matrix, or in certain cases, both. When the amount of ROS produced within the 
mitochondrial matrix exceeds a threshold amount, unique to physiological 
functioning of the cell, there can be an irreversible opening of the mPTP (119) 
(Figure 5). In steady state, this pore within the inner mitochondrial membrane 
switches rapidly between a close to an open to a close state again, maintaining 
mitochondrial membrane potential and allowing transfer of essential molecules 
across the mitochondrial membrane (119). Under conditions of dysregulated 
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ROS production, increase in levels of ROS is accompanied by a fall in the 
mitochondrial membrane potential and subsequent opening of the mPTP (120, 
121) (Figure 5). The latter is an irreversible signal for unhealthy mitochondria to 
either trigger apoptosis by disintegration of the ETC and release of Cytochorome 
c into the cytosol, or be cleared by autophagic proteins interacting with signals 
triggered through high levels of ROS in order to maintain cellular viability (122, 
123, 124). 
 
Figure 1.5. ROS and opening of mitochondrial permeability transition pore. 
Adapted from Zorov et al. 
ROS in inflammation 
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While the injurious reactivity of radical oxidants is a threat to cell viability 
and can trigger cell death, ROS has also recently been implicated in acting as 
signaling factors contributing to certain cellular functions. It has been proposed 
that ROS can interact with “ROS receptors” such as the KEAP1-NRF2 complex 
which plays a role in maintaining oxidative homeostasis by regulating expression 
of endogenous antioxidants, among other molecule (125, 126). In addition to this, 
ROS upregulated in the context of infection through PAMP activated TLRs has 
also been shown to upregulate cytokines such as IL6 by inhibition of negative 
regulators such as proteases that cleave MAP kinases (127, 128). Alternatively, 
there is also evidence to implicate ROS in the IL1-b mediated activation of the 
NLRP3 inflammasome (129, 130). Moreover, further implications of crosstalk 
between ROS and cytokines comes from recent evidence suggesting that TNFa 
mediated activation of the TNF receptor pathway can also upregulate 
mitochondrial ROS (131, 132, 133). While there is some contradictory evidence 
of ROS being able to activate NF-kB in specific circumstances, the generally 
accepted consensus is that TNF mediated upregulation of ROS can deactivate 
NF-kB as an intrinsic regulatory mechanism for shutting down intracellular 
processes as part of programmed cell death (134, 135). 
Cell Death 
Multiple metabolic cues can converge within a cell to orchestrate 
programmed cell death in order to meet demands of broader physiological 
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functions involved in embryogenesis and elimination of cells injured beyond 
possibility of repair, among others. Apoptosis is the most well characterized form 
of programmed cell death mediated by cysteine proteases called caspases. In 
steady state, the two major types of caspases- initiator caspases and effector 
caspases reside within the cytoplasm (136). Cell intrinsic apoptosis is primarily 
triggered by pro apoptotic factors residing within the mitochondria (124). 
Upregulation of ROS, depolarization of mitochondrial membrane and irreversible 
opening of the mPTP releases components of the ETC into the cytosol, including 
cytochrome c (122, 123). Released cytochrome c then works through a series of 
coordinated steps to activate initiator caspases like caspase 9 that in turn go on 
to activate effector caspases 3 and 7 in a domino effect (137, 138). Effector 
caspases are capable of cleaving multiple cellular proteins as part of the 
apoptotic machinery. It is also worthwhile to note that apoptosis can also be 
executed in a mitochondria independent cell extrinsic process through activation 
of caspase 8 (139, 140). 
Although apoptosis is considered to be the most evolutionarily conserved 
form of programmed cell death, there are certain other non-apoptotic forms of 
cell death that can work independently or in line with apoptosis for cell killing 
(Figure 6). One such non-apoptotic form of cell death is Necroptosis (141). While 
TNFa mediated activation of the TNFR is the primary activator of Necroptosis, 
TL3 or TLR4 stimulation has also been implicated this process (142, 143, 144, 
145, 146). Activation of these signaling pathways ultimately lead to the 
deubiquitylation of a proteins kinase called RIPK1 allowing it to interact with 
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another kinase called RIPK3 to generate a complex called the Necrosome (147, 
148). This, on one hand can activate ROS production by the mitochondria and on 
the other hand can induce cellular swelling or oncosis and rupture of the plasma 
membrane mediated by the phosphorylated and oligomerized form of the 
pseudokinase MLKL (149, 150). Another form of non-apoptotic cell death is 
pyroptosis. This type of cell death is mainly reliant on cytokines such as IL-1a 
and IL-1b in a caspase 1 mediated process that ultimately leads to cell lysis as 
seen in Necroptosis (151). 
Although cell death is one viable option to eliminate damaged cells, in 
certain circumstances, killing of the cell can be circumvented by targeting 
damaged organelles or cellular components to intracellular structures for 
degradation. This process is known as autophagy (152). The general mechanism 
of autophagy involves damaged cellular components to be targeted to double 
membrane bound autophagosomes which can then fuse with lysomes to induce 
degradation through the action of lysosomal hydrolases (153, 154). There are 
many proteins highly conserved across mammals that constitute the autophagy 
machinery, including Beclin-1 which initiates the process and Atg8 or LC3 which 
is required to be inserted into the autophagosome membrane required for 
expansion of the autophagosome to encapsulate intracellular components and its 
subsequent fusion with lysosomes (155, 156). This process of autophagic 
removal of damaged molecules can be regulated by multiple factors, including 
mitochondrial generation of ROS. Both superoxide anion (O2.-) and hydrogen 
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peroxide (H2O2) have been implicated in triggering autophagy (157, 158, 159). 
However, recent evidence also reveals a mutually suppressive role of 
mitochondrial ROS mediated activation of apoptosis, and initiation of autophagy, 
with the latter suppressing factors within the mitochondria to inhibit apoptosis. 
Indeed, it has been shown that suppression of autophagy can upregulate 
mitochondrial ROS levels with a concurrent depolarization of the mitochondrial 
membrane, a release of cytochrome c into the cytosol and activation of apoptosis 
(160, 161). 
 
Figure 1.6. Intrinsic cellular processes triggered in response to cellular 
injury. Adapted from Fink and Cookson et al. 
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           Anemia of Inflammation 
Diseases and evolutionary rationale 
A majority of microorganisms, including many pathogens require iron as 
an essential element for biological processes. They require iron as an essential 
component of enzymes participating in oxidative phosphorylation, DNA 
replication, to maintain overall cellular morphology, in production of toxins and 
other processes. Their iron requirement in certain cases exceeds their available 
iron stores, therefore many pathogens have elegant mechanisms to acquire iron 
from host sources. Sometimes this iron availability from host sources allows an 
opportunistic pathogen to establish infection and damage host cells (162, 163, 
164). As a result of this, host iron stores and availability are tightly linked to 
disease susceptibility, onset of infection and subsequent prognosis. Patients with 
hereditary hemochromatosis (iron overload), high iron levels due to repeated 
blood transfusions, or medical regimens that include high levels of oral or 
parental iron supplementation, as well as consumption of iron rich diets have 
been found to be susceptible to acute infections by pathogens such as Vibirio 
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vulnificus, Yersinia enterolitica, Yersinia pestis, etc (165, 166, 167). 
Pathophysiology of many chronic inflammatory conditions including kidney 
disease, diabetes, neurodegeneration, inflammatory bowel disorder, rheumatoid 
arthritis, etc has also been linked to high levels of iron in the body (5, 10, 11). 
This link between iron loading and inflammation, whether acute or chronic, 
underlies the evolution of AI (also known as Anemia of Chronic disease), wherein 
the body adapts to an iron deficient state to ameliorate inflammation and resist 
infection by pathogens. 
Primary mechanism and signaling pathway 
Many bacterial infections release ligands TLRs for example 
lipopolysaccharide-a TLR4 ligand. Activation of the TLR pathway results in an 
NFkB mediated production of inflammatory mediators, including the pro 
inflammatory cytokine IL6 that has been implicated in causing anemia by 
upregulating Hepcidin (168, 169, 170, 171, 172). IL6 treatment in cultured 
Hepatocytes and HepG2/2.2.1 cells upregulated Hepcidin mRNA expression. IL6 
binding to the IL6 receptor triggers activation of the JAK-STAT pathway. STAT3 
is phosphorylated and becomes capable of translocating to the nucleus and 
binding to the hepcidin promoter, inducing hepcidin expression (Figure 7). In 
HepG2/2.2.1 cells treated with IL6, chromatin immunoprecipitation studies 
revealed binding of STAT3 to the Hepcidin promoter (172).  
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Figure 1.7. IL6 activation stimulates the Hepcidin promoter. Adapted from 
Hentze et al. 
Hepcidin in turn causes hypoferremia by preventing iron export through 
the internalization and degradation of Ferroportin (described previously in this 
chapter). Degradation of Ferroportin leads to an intracellular retention of iron 
within cells such as macrophages and a concurrent fall in iron availability for 
erythroid progenitor generation. Thus, a state of IRE ensues, with high levels of 
iron entrapped in the reticuloendothelial system -both of which are classic 
hallmarks of anemia of inflammation. In contrast with a normal state of iron 
absorption, IRE is characterized by low plasma iron but elevated iron 
accumulation within cells such as macrophages (173, 174). (Figure 8). 
Additionally, it has also been suggested that inflammation independent STAT3 
activation can also induce Hepcidin expression and regulate iron availability, 
further underscoring the importance of this pathway as the primary cause of 
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anemia in anemia of inflammation (172). Although Hepcidin is upregulated 
immediately following administration of an inflammatory insult, in an 
erythropoietic stimulation model of AI in mice, it was found that under conditions 
of anemia, serum hepcidin levels begin to decline as early as 14 days following 
erythropoietic stimulation (175). This indicates a potential generation of iron 
overload conditions at later time points, giving rise to the possibility of NTBI 
mediated damage in AI.  
  
Figure 1.8. Hallmarks of IRE induced by changes in iron homeostasis 
under inflammation. Adapted and modified from Lee et al. 
Additional causes of anemia of inflammation 
Another cytokine implicated in IRE is IL1. Primary murine hepatocytes 
from IL6-/- mice were capable of inducing Hepcidin expression, and only failed to 
induce Hepcidin in the presence of blocking antibodies for IL1-a, IL1b and IL6 
(176). IL1 induces Hepcidin expression through C/EBPa, a transcriptional 
regulator of Hepcidin (177, 178). This transcription factor also has independent 
contributions to anemia of inflammation through the ER stress pathway. Cellular 
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damage can trigger activation of the ER unfolded protein response. ER stress 
response proteins can downregulate expression of CHOP, which is a negative 
regulator of C/EBPa. Relieving repression of C/EBPa contributes to Hepcidin 
expression and subsequent anemia (179, 180, 181). 
HMGB1, a cytokine mediator of inflammation produced by cells such as 
macrophages, is capable of binding to the MD-2-TLR4 complex, resulting in 
NFkB mediated production of cytokines like IL6 that cause IRE (182, 183). TLR2 
and TLR4 can also induce iron sequestration and IRE in a hepcidin independent 
manner. TLR pathways can trigger the production of Lipocalin-2 by 
macrophages. Lipocalin is an acute phase protein implicated in iron 
sequestration (184, 185). Another acute phase protein is Ferritin. In steady state, 
Ferritin is an intracellular protein, and apoferritin binds to ferrous iron and stores 
it as ferric iron within cells, including those of the reticuloendothelial system 
(186). Although small amounts of Ferritin are secreted in steady state, under 
inflammatory conditions, levels of extracellular plasma ferritin increase and can 
be used as an indicator of inflammation (187, 188, 189). Whether this ferritin can 
extracellularly bind to iron from a labile iron pool in the serum remains to be 
seen. Additionally, inflammatory TLR mediated stimulation of neutrophils can 
result in the production of Lactoferrin, a homolog of Tf which unlike Tf does not 
release Iron in the low pH of the endosomal system, contributing to yet another 
arm of iron sequestration in the face of infection (190). Inflammatory mediators 
can also contribute to the production of Nramp-1, a phagosomal transporter that 
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sequesters iron and prevents its acquisition by invading pathogens (191, 192). 
Multiple erythropoiesis associated genes involved in the anemia of inflammation 
response including Nramp1, ferroportin, DMT1, TfR1 and erythropoietin are also 
regulated by the family of HIFs (Hypoxia inducible factors), and in turn HIF1-a is 
transcriptionally controlled by NFkB thereby linking the inflammatory signaling 
pathways to a HIF mediated regulation of iron homeostasis (193, 194).  
Mouse models of anemia of inflammation 
While in vitro culture systems can be used to study some features of AI, 
the mouse physiological system, due to its close similarity to humans has been 
adapted as an ideal model for investigation into various aspects of AI. There are 
other mammalian and non- mammalian models also available for studying AI, but 
due to its relative ease of handling, reproducibility, and extensive erythropoietic 
response mimicking that of humans, the mouse model remains the most 
preferred one. 
Non-infectious mouse models of AI include injection of Turpentine and 
models imitating autoimmune conditions such as collagen induced arthritis for 
examining certain features of rheumatoid arthritis and an oral administration of 
dextran sulfate sodium to model inflammatory bowel disease. While these 
models do induce significant anemia, increased Hepcidin expression is not 
always maintained (195, 196, 197, 198). Moreover, results are often unique to 
the type of disease under investigation, and might not be an accurate 
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representation of acute inflammatory conditions. 
Certain infectious models are also in practice for studying AI. These 
include CLP and introduction of catheters or dextran microbeads coated with 
bacteria such as Staphylococcus epidermidis, Staphylococcus pyogenes, 
Staphylococcus aureus. These mice do develop mild but significant anemia, 
although not always associated maintenance of elevated Hepcidin levels. There 
are however technical difficulties often associated with CLP, and higher 
morbidity, which has since limited the use of this model for studying AI (199, 
200). 
Currently, pseudo-infectious models are the most extensively studied 
models for investigating AI. These involve the use of immunogenic particles 
derived from infectious organisms that are able to mimic the inflammatory 
response in a disease setting to a certain extent and also simultaneously display 
hallmarks of IRE. A single IP injection of CFA was able to induce iron restricted 
anemia characterized by drop in hemoglobin and MCV levels. Injection of 
lipopolysaccharide has also been demonstrated to cause anemia in mice (201, 
202, 203). 
A recent and effective pseudo-infectious mouse model to study AI involves 
a single IP injection of the Brucella ring test antigen consisting of heat-killed 
particles of the gram-negative bacterium Brucella abortus. Two weeks after 
injection of BA, WT mice show the lowest level of hemoglobin, a significant drop 
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by 5-6 g/dL in comparison to controls (205). This anemia is iron restricted and 
more severe in comparison to the other mouse models discussed previously. 
Anemia is also accompanied by a rise in serum Hepcidin and a concurrent fall in 
serum iron levels as early as 6 hours after injection of BA. Although IRE is the 
primary cause of hypoferremia in this model, the kinetics of drop in hemoglobin 
so early in the response also suggest possible RBC hemolysis contributing to 
anemia (173, 204, 205, 206, 207, 208). 
Existing information on the contribution of IL6 in AI 
Existing literature and previous work by us elucidates the significance of 
IL6 and Hepcidin in AI. In both the IL6-KO and Hamp-KO mice injected with BA, 
recovery was found to be improved in terms of CBC parameters, in comparison 
to WT controls. However, the IL6-KO mice showed improved erythropoiesis in 
the BM a week after BA administration, in comparison to iron overloaded Hamp-
KO mice (173) (Figure 9). On observing these differing modes of recovery in IL6-
KO and Hamp-KO mice, we wanted to further study the cellular responses 
governing erythroid recovery in the absence of IL6 under inflammatory insult, and 
additionally, the influence of iron and iron overloading conditions on BM 
erythropoiesis under the same. The results of our study are described in the next 
chapter.	
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Figure 1.9. IL6 KO mice show improved BM erythropoiesis under AI. 
Adapted from Gardenghi et al. 
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Chapter Two 
 
Results: Lack of IL6 protects erythroid recovery under AI, a process 
reversible by iron dependent ROS upregulation 
 
 
 
 
Summary: In our study, we show that under inflammatory insult, terminal 
erythroid differentiation within the BM is improved in the absence of IL6. We 
further demonstrate that this lack of IL6 mediated protective effect is lost in 
conditions of iron overload, by a ROS dependent detrimental effect on BM 
erythropoiesis. 
 
The IL6-KO mice showed improved BM erythropoiesis two weeks after BA 
administration with a concurrent regression in BM erythroid recovery of the DKO 
Considering existing information on the different patterns of erythroid 
recovery in IL6-KO and the iron overloaded Hamp-KO, we generated a DKO of 
IL6 and Hamp, to investigate potential independent roles of the two genes in AI 
and furthermore, to study BM erythropoiesis of the IL6-KO in the context of iron 
overloading. The IL6-KO, Hamp-KO and DKO showed an improved erythroid 
recovery in comparison to the WT (Fig 1A, B, C, D). Despite this improved 
recovery, both iron overloaded models (the DKO and the Hamp-KO) showed 
similar hemoglobin levels, MCV, MCH and RBC (Fig 1A, B, C, D).  
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Figure 2.1. Both iron overloaded models of Hamp- KO and the DKO show 
similar recovery of peripheral blood hemoglobin levels under AI. * P< 0.05, 
** P <0.01, *** P < 0.001. (A) Hemoglobin levels in peripheral blood of WT, IL6-
KO, Hamp-KO and DKO mice. Peripheral blood was collected at 0, 1, 2, 3, 4, 5, 
and 6 weeks after injection of BA (Mean±SD, n=15, results are representative of 
two independent experiments). (B) As in (A), but for MCV (mean corpuscular 
volume) levels. (C) As in (A), but for MCH (mean corpuscular hemoglobin) levels. 
(D) As in (A), but for RBC levels. (E) Percentage of biotinylated RBC in 
peripheral blood of WT mice injected with biotin and injected with BA, as 
measured by flow cytometric analysis of peripheral blood. Biotinylated RBC 
measurement was done at 0, 4, 7, 11 and 14 days after injection of BA 
(Mean±SD, n=5, statistics are in comparison with PBS injected control mice). 
 
The DKO however, solely showed a biphasic effect in reticulocyte count, 
with numbers that peaked one week after BA administration, and then dropped 
on the second week (Fig 2A). To confirm this initial rise in peripheral blood count 
and subsequent fall, we measured RBC lifespan at similar time points-one and 
two weeks after BA injection. Unlike RBC life span in the WT injected with BA 
(Fig 1E), the IL6-KO, Hamp-KO and the DKO all show a decrease in production 
of biotinylated RBCs on BA injection, indicating production of new “non-
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biotinylated” RBCs in response to the anemia (Fig 2B, C, D). However, the DKO 
shows the drop in biotinylated RBCs one week following BA administration, 
indicating an accelerated production of new RBCs in comparison to the IL6-KO 
and the Hamp-KO where the drop occurs 11 days after BA administration. (Fig 
2B, C, D). This accelerated production of new RBCs in the DKO (Fig 1B) occurs 
at the same time as the rise in its reticulocyte count (Fig 2A). Furthermore, 
although the percentage of biotinylated RBCs initially continues to decrease upon 
BA administration, this decrease pauses after day 11 and the curve plateaus 2 
weeks after BA administration (Fig 2B) indicating a potential suspension in the 
generation of new RBCs. This time point also coincides with the fall in 
reticulocyte count of the DKO, seen two weeks following inflammatory insult (Fig 
2A). 
 
 
Figure 2.2. The DKO displays a biphasic trend in peripheral blood cell 
count. * P< 0.05, ** P <0.01, *** P < 0.001 (A) As in Figure1A, but for reticulocyte 
count. (B) Percentage of biotinylated RBC in peripheral blood of DKO mice 
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injected with biotin and injected with BA, as measured by flow cytometric analysis 
of peripheral blood. Biotinylated RBC measurement was done at 0, 4, 7, 11 and 
14 days after injection of BA (Mean±SD, n=5, statistics are in comparison with 
PBS injected control mice). (C) As in (B), but in IL6-KO mice. (D) As in (B) but in 
Hamp-KO mice. 
 
 
 
Following our study on peripheral blood count, we assessed BM terminal 
erythroid differentiation of all four genotypes after BA injection, to confirm 
maintenance of a biphasic effect in the DKO. Immediately following inflammatory 
insult, when we looked at BM erythropoiesis 3 days after injection of BA, we 
found that the WT, Hamp-KO, IL6-KO and the DKO showed a drastic reduction in 
erythroid progenitor differentiation in response to the inflammation (Figure 3A). 
Early in the response to BA, all four genotypes were equally affected in BM 
erythropoiesis. However, one week after administration of BA, we find that the 
IL6-KO, Hamp-KO and the DKO began to show an improvement in BM erythroid 
progenitor differentiation, in comparison to the WT. (Fig 3B). Nonetheless at this 
time point, the DKO shows the highest improvement in terminal erythroid 
differentiation, with the maximum expansion of erythroid progenitor populations in 
comparison to the single KOs (Fig 3B). Since, one week following inflammatory 
insult we detected an improvement in erythroid progenitor differentiation, we 
quantified the absolute cell numbers of each progenitor population at this time 
point and further confirmed the improved BM terminal erythroid differentiation of 
the DKO (Fig 4A). In agreement with the biphasic effect seen previously, this 
improved erythroid recovery in the DKO regressed, and the IL6 KO showed the 
most improved BM erythroid differentiation two weeks after administration of BA 
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(Fig 3C). This significant improvement of BM erythropoiesis following 
inflammatory insult in the IL6-KO was quantified and confirmed by absolute cell 
numbers of the progenitor populations (Fig 4B). 
 
 
 
Figure 2.3. Two weeks following inflammatory insult, the IL6-KO shows the 
most improved Bone Marrow (BM) erythroid recovery with a concurrent 
regression in the same of the DKO. (A) Flow cytometric analysis of BM in WT, 
Hamp-KO, IL6-KO and DKO; 72 hours after injection with BA. CD71 (Transferrin 
receptor), TER119 (erythroid specific) and CD44 (adhesion molecule that 
progressively decreases in expression from pro-erythroblast to reticulocyte 
stage) were used. TER119+CD71+ and TER119+CD71- cells (Erythroid 
precursors and mature RBCs respectively-not shown here) were selected and 
plotted as CD44 versus FSC, to show the different stages of terminal erythroid 
differentiation. Differentiation occurs as indicated by the direction of the arrow, 
and includes (I) pro-erythroblast, (II) basophilic erythroblast, (III) polychromatic 
erythroblast, (IV) Orthochromatic and reticulocyte, and (V) mature RBCs. (B) As 
in (A) but showing flow cytometric analysis of BM in WT, Hamp-KO, IL6-KO and 
DKO; one week after injection with BA. (C) As in (A) but two weeks after injection 
with BA. 
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Figure 2.4. Quantification of progenitor cell numbers in the BM confirm 
improved erythroid recovery of the IL6-KO. (A) Quantification of the flow 
cytometric dot plots in Fig 3B. Absolute number of cells for each erythroid 
population (color coded and labelled as P1, P2, P3, P4 and P5, in the flow 
cytometric dot plot legend) were plotted as bar graphs with each color in the bar 
graph corresponding to the matching color and population in the flow cytometric 
dot plot legend. Bar graphs representing PBS injected (Left bar) and BA injected 
(right bar) in WT, Hamp-KO, IL6-KO and DKO mice are shown. (B) Quantification 
of the flow cytometric dot plots in Fig 3C, quantified as in Fig 4A. 
 
 
 
Furthermore, the spleen of all genotypes showed extra medullary 
erythropoiesis one and two weeks following BA administration, with no difference 
in splenic expansion of erythroid progenitor populations within the IL6-KO, Hamp-
KO and DKO (Fig 5A, B). Interestingly, this phenomenon is then organ specific, 
as only the BM is affected and not the spleen.  
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Figure 2.5. The spleen shows no significant difference in extra medullary 
erythropoiesis, between the Hamp-KO, IL6-KO and the DKO. Flow cytometric 
analysis of Spleen in WT, Hamp-KO, IL6-KO and DKO; one week after injection 
with BA. Terminal erythroid differentiation is analyzed by flow cytometry as 
described in Figure 3. n=5, each flow cytometric dot plot is representative of one 
animal per group. (B) As in (A) but two weeks after injection with BA. 
 
 
 
Based on the above trend in erythroid recovery that we noted in all four 
genotypes, we found two major phases of BM erythroid recovery under 
inflammation in a schematic representation of changes in BM erythroid progenitor 
cell numbers over time (Fig 6). The first phase is seen immediately following BA 
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administration. This phase, which been studied previously in literature by others 
and by us, is characterized by an upregulation of cytokines and severely reduced 
terminal erythroid differentiation in the BM of all genotypes (Fig 6, Fig 3A). 
Although the cytokine response and erythroid parameters in the first phase have 
been elucidated before, we were able to identify a second phase of BM erythroid 
response under inflammation. This second phase is characterized by a 
regression in erythroid recovery of the DKO and a concurrent improved recovery 
of the IL6-KO (Fig 6, Fig 3C). At this phase, the WT and the Hamp-KO continue 
to show a slackened BM erythropoiesis in response to the inflammation.  
 
Figure 2.6. Pattern of BM erythroid recovery in the different genotypes 
reveals two major phases of divergence, phase one and phase two. 
Schematic representation of changes in numbers of BM erythroid progenitor 
populations (indicated by the different lines) in the WT, IL6-KO, Hamp-KO and 
DKO at different time points following BA injection. 
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In phase one of recovery under AI, both the WT and IL6-KO show an 
increase in levels of mitochondrial SO within BM erythroid progenitors 
Given the extensive evidence supporting crosstalk between ROS and iron 
homeostasis, in order to investigate cellular responses contributing to BM 
erythroid recovery under AI, we looked at changes in ROS generation in the two 
different phases of recovery following BA administration. As shown previously, 
we found an expected fall in terminal erythroid differentiation within the BM of WT 
and IL6-KO mice, 72 hours after injection of BA, in the first phase (Fig 7A, Fig 
3A).  This initial blunted erythropoietic response is also accompanied by 
upregulated cytokine levels, noted previously by others and by us (Fig 8). We 
found that this fall in terminal erythroid differentiation following BA administration 
in both the WT and the IL6-KO was preceded by an increase in levels of 
mitochondrial SO, 24 hours after BA injection, in both the WT and the IL6-KO 
(Fig 7B). 
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Figure 2.7. During phase one of recovery under inflammation, 
mitochondrial superoxide levels within BM erythroid progenitors increase 
in both the WT and the IL6-KO. * P<0.05, ** P<0.01, *** P<0.001. (A) Flow 
cytometric representation of terminal erythroid differentiation (as described in 
Figure 3), for WT and IL6 KO mice 3 days after BA injection, n=5. (B) Flow 
cytometric analysis of mitochondrial superoxide of BM erythroid progenitors in 
WT and IL6-KO mice 24 hours after injection of BA. (from right to left) To select 
for erythroid progenitors, TER119 (erythroid specific) and CD29 (integrin that 
progressively decreases in expression from pro-erythroblast to reticulocyte stage 
and can distinguish between the orthochromatic and reticulocyte stage by 
difference in expression) were used. TER119+ cells were selected and plotted as 
CD29 versus FSC and subsequently the pro-erythroblast to orthochromatic 
stages were selected for analyzing mitochondrial superoxide (SO) expression by 
histogram. Cells in the histogram were gated into SO positive, indicating cells 
with high expression of SO (extreme right panel of B.) Histogram of SO 
expression on cells of these selected erythroid progenitor stages in PBS and BA 
injected mice is shown, red line indicates PBS injected control and blue line 
indicates BA injected. Percentage of cells in the SO positive gates were plotted in 
bar graphs, red bars indicate PBS injected and blue bars indicate BA injected. 
n=3, histogram of sample from one representative mouse is shown. 
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Figure 2.8. In phase one of recovery under inflammation, both WT and IL6-
KO upregulate serum cytokines. * P<0.05, ** P<0.01, *** P<0.001 (A) IFN y 
and TNF⍺ cytokine levels in serum of WT and IL6-KO mice 24 hours after 
injection of BA, in comparison to PBS injected controls were plotted in bar 
graphs. Blue bars indicate WT and orange bars indicate IL6-KO, n=5. 
 
 
 
 
In phase two of recovery under AI, WT erythroid progenitors upregulate 
expression of ROS, while the IL6 KO does not 
Two weeks after BA injection, we identified a second phase of erythroid 
response to BA which, similar to phase one, was characterized by an 
upregulation of cytokines IFNy and TNFa in both the WT and the IL6-KO mice 
(Fig 9A). Unlike the response in phase one, under the second phase of recovery 
under inflammation, the IL6-KO showed improved BM erythropoiesis in 
comparison to the WT, two weeks after injection of BA (Fig 9B, Fig 3C). This 
divergence in erythroid recovery between the IL6-KO and the WT was also 
preceded by a divergence in mitochondrial SO production by BM erythroid 
progenitors of the two genotypes, 10 days after injection of BA. We found that, 
the IL6-KO which showed improved erythroid recovery, normalized mitochondrial 
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SO in the second phase, in comparison to the WT which continued to show 
upregulated mitochondrial SO (Fig 9C).  
 
 
Figure 2.9. During phase two of recovery under inflammation, 
mitochondrial superoxide levels within BM erythroid progenitors increase 
in the WT but not in the IL6-KO. * P<0.05, ** P<0.01, *** P<0.001 (A) IFN y and 
TNF⍺ cytokine levels in serum of WT and IL6-KO mice 2 weeks after injection of 
BA, in comparison to PBS injected controls were plotted in bar graphs. Blue bars 
indicate WT and orange bars indicate IL6-KO, n=5 (B) Flow cytometric 
representation of terminal erythroid differentiation (as described in Figure3), for 
WT and IL6 KO mice 2 weeks after BA injection. n=9. (C) Flow cytometric 
analysis of mitochondrial superoxide of BM erythroid progenitors in WT and IL6-
KO mice 10 days after injection of BA, analyzed as in Figure 7. n=3, histogram of 
sample from one representative mouse is shown. 
 
 
 
 
This divergent pattern of mitochondrial SO generation between the two 
groups in the second phase of recovery under AI prompted us to investigate 
ROS generation further in this phase. Two weeks after administration of BA, BM 
erythroid progenitors of the WT upregulated expression of cytoplasmic ROS, 
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while the IL6-KO was protected (Fig 10A). Moreover, at the same time, the WT 
showed an increase in total protein oxidation of whole BM cells, but the IL6-KO 
did not (Fig 10B). It is noteworthy that this lack of ROS upregulation in the IL6-
KO two weeks after inflammatory insult coincides with an improved BM 
erythropoiesis (Fig 9B, Fig 3C).  
 
 
Figure 2.10. During phase two of recovery under inflammation, cytoplasmic 
ROS levels within BM erythroid progenitors increase in the WT but not in 
the IL6-KO. * P<0.05, ** P<0.01, *** P<0.001 (A) Flow cytometric analysis of 
cytoplasmic ROS of BM erythroid progenitors two weeks after injection of BA. 
Eryhthroid progenitors were selected by flow cytometric analysis (as in Figure 7). 
Cytoplasmic ROS levels in these selected erythroid progenitors is shown by a 
histogram of the general oxidative indicator CM-H2DCFDA. Red lines indicate 
PBS injected and blue lines indicate BA injected. n=9, histogram of sample from 
one representative mouse is shown. The MFI of the histogram were plotted in bar 
graphs, red bars indicate PBS injected and blue bars indicate BA injected. (B) 
Oxyblots indicating total protein oxidation of whole BM cells two weeks after 
injection with BA. n=4, one oxyblot from one representative mouse is shown. 
Increase in signal of the blot indicates increase in total protein oxidation. Signal 
density of the oxyblots were quantified into bar graphs by image J; red bar 
indicates PBS injected and blue bar indicates BA injected.  
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When we examined erythroid progenitors in the spleen two weeks after 
BA administration, we found no change in cytoplasmic ROS expression in splenic 
erythroid progenitors of either the WT or the IL6-KO mice (Fig 11A), in 
agreement with no defect in erythroid production in this organ. Moreover, upon 
BA administration, we found no change in total protein oxidation within the WT 
spleen, and a decrease in total protein oxidation in the IL6-KO spleen (Fig 11B).  
 
 
Figure 2.11. During phase two of recovery under inflammation, the spleen 
is protected from ROS upregulation. (A) As in Fig 10A, but indicating 
cytoplasmic ROS levels in splenic erythroid progenitors, two weeks after injection 
of BA, n=9. (B) As in Fig 10B, but indicating total protein oxidation of whole 
spleen cells two weeks after injection of BA, n=4. 
 
 
  
 
Improved BM erythropoiesis of the IL6 KO under inflammation is 
reversible in the presence of iron 
We postulated that ROS upregulation is potentially a physiological by 
product of stress erythropoiesis and not necessarily detrimental to erythroid 
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recovery. However, upregulated ROS can impair erythroid recovery in the 
presence of high levels of iron. We further hypothesized that although lack of IL6 
is protective in phase two of response, lack of IL6 in combination with conditions 
of iron overload exacerbates the latter’s effect on impeding terminal erythroid 
differentiation in the BM. In line with our hypothesis, we found that in WT mice 
phlebotomized to induce acute stress erythropoiesis, ROS was upregulated in 
BM erythroid progenitors (Fig 12A). Since erythropoiesis under stress is not 
impaired, but rather shows an expansion of the erythroid progenitor pool to meet 
demands of erythrocyte generation, this upregulation of ROS accompanying 
stress is potentially a physiological by product. Subsequently, in IL6-KO mice iron 
overloaded by injection of iron dextran, we found that two weeks following BA 
administration, cytoplasmic ROS of BM erythroid progenitors is increased (Fig 
12B). This upregulated cytoplasmic ROS is accompanied by a concurrent 
blunted erythroid differentiation in the BM of the iron overloaded IL6-KO mice 
(Fig 12C). Given that the DKO is also IL6-deficient but overloaded with iron (due 
to lack of Hamp), we also looked at cytoplasmic ROS expression in the Hamp-
KO and the DKO. We find that two weeks after injection of BA, the Hamp-KO and 
DKO upregulate cytoplasmic ROS in their BM erythroid progenitors (Fig 12D). 
This upregulated ROS was accompanied by an impaired or delayed BM 
erythropoiesis, particularly in the DKO (Fig 12E), in line with our hypothesis that 
lack of IL6 in combination with iron overload is deleterious to BM erythroid 
differentiation. Furthermore, diminished BM erythropoiesis and upregulated ROS 
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in the DKO and the Hamp-KO was also accompanied an upregulation of the 
cytokines IFNy and TNFa in both the genotypes (Fig 12F). 
 
 
Figure 2.12. ROS upregulation is a physiological by-product of stress 
erythropoiesis, but becomes detrimental in the presence of iron overload. * 
P<0.05, ** P<0.01, *** P<0.001 (A) Flow cytometric analysis of cytoplasmic ROS 
of BM erythroid progenitors in mice phlebotomized to induce acute stress 
erythropoiesis. Cytoplasmic ROS expression in erythroid progenitors was 
measured and quantified as described in Figure 10A. n=3, histogram of sample 
from one representative mouse is shown. (B) Flow cytometric analysis of 
cytoplasmic ROS of BM erythroid progenitors in PBS and BA injected IL6-KO 
mice without and with the injection of iron dextran to induce iron overload. 
Cytoplasmic ROS expression in erythroid progenitors was measured and 
quantified as described in Figure 10A. n=4, histogram of sample from one 
representative mouse is shown. (C) Flow cytometric analysis of BM terminal 
erythroid differentiation (selection method described in Figure 3) in BA injected 
IL6-KO mice without and with the injection of iron dextran to induce iron overload. 
n=4, flow cytometric dot plots of a sample from one representative mouse is 
shown. Red box indicates erythroid progenitors. (D) Flow cytometric analysis of 
cytoplasmic ROS of BM erythroid progenitors in PBS and BA injected Hamp-KO 
and DKO mice. Cytoplasmic ROS expression in erythroid progenitors was 
measured and quantified as described in Figure 10A.  n=5, histogram of sample 
from one representative mouse is shown. (E) Flow cytometric representation of 
terminal erythroid differentiation (as described in Figure 3), for Hamp-KO and 
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DKO mice 2 weeks after BA injection. Red box indicates erythroid progenitors, 
n=5. (F) IFN y and TNF⍺ cytokine levels in serum of Hamp-KO and DKO mice 2 
weeks after injection of BA, in comparison to PBS injected controls were plotted 
in bar graphs. Grey bars indicate Hamp-KO and yellow bars indicate DKO, n=5. 
 
 
 
 Additionally, when we looked at ROS generation in splenic erythroid 
progenitors of BA injected IL6-KO mice with and without the treatment of iron 
dextran to induce iron overload, we found no difference (Fig 13A). Moreover, the 
spleen of the Hamp-KO and the DKO show no increase in cytoplasmic ROS and 
remain protected (Fig 13B). 
 
 
Figure 2.13. The spleen is protected from ROS upregulation under 
conditions of iron overload. As in Fig 12B; but indicating cytoplasmic ROS in 
splenic erythroid progenitors of IL6-KO mice, without and with the injection of iron 
dextran to induce iron overload and additionally showing erythroid differentiation 
in the spleen under the same conditions, n=4. (B) As in Fig 12D, but indicating 
cytoplasmic ROS levels in splenic erythroid progenitors of Hamp-KO and DKO 
mice, two weeks after injection of BA, n=5. 
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Finally, to investigate the presence of NTBI in the WT mice, as an 
explanation of ROS possibly impairing BM erythroid recovery in these animals, 
we looked at serum iron and transferrin saturation two weeks after administration 
of BA. We found that although the serum iron showed no difference upon BA 
injection in the second phase of recovery (Fig 14A), the transferrin saturation 
decreases (Fig 14B) indicating presence of iron in the serum not bound to 
transferrin potentially capable of damage in this phase. 
 
 
 
Figure 2.14. During phase two of recovery under inflammation, the WT 
shows presence of iron in the serum not bound to transferrin. * P<0.05, ** 
P<0.01, *** P<0.001 (A) Serum iron in PBS and BA injected WT mice two weeks 
after injection of BA, n=5. (B) Transferrin saturation in PBS and BA injected WT 
mice two weeks after injection of BA, n=5. 
 
Based on this above data, we were able to generate a model of erythroid 
recovery under AI, in the context of iron overloading conditions and lack of IL6 
(Fig 15). Under stress erythropoiesis, BM erythroid progenitors can upregulate 
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production of ROS. Under inflammation, this upregulated ROS produced as a 
result of erythropoietic stress can downregulate erythroid recovery in the BM. 
This ROS mediated impaired erythroid recovery can be inhibited by lack of IL6 
but this protective effect under absence of IL6 is reversed in the presence of 
either high levels of iron or by a concurrent absence of Hamp. 
 
 
 
 
Figure 2.15. A model of erythroid recovery under AI. Under condition of 
stress erythropoiesis, erythroid progenitors upregulate production of ROS. Under 
inflammation, this stress mediated upregulation of ROS impairs erythroid 
recovery. Absence of IL6 inhibits upregulated ROS but this process is reversible 
under conditions of iron overload, by lack of Hamp or administration of iron. 
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Chapter Three 
 
Methods 
 
BA induced model of inflammation 
Heat killed Brucella abortus was acquired from the United States Department of 
Agriculture, National Veterinary services laboratories and prepared as described 
by Sasu et al (204). A single dose of 5 X 108 particles of BA was injected IP in 
mice, which were sacrificed at the stated time points for harvesting organs, 
processing cells, and further analysis. All animals were age and sex matched-
male and five months of age. WT and IL6-KO mice were purchased from 
Jackson Laboratories, and Hamp-KO mice were a gift from the laboratory of Dr. 
Thomas Ganz at UCLA. Peripheral blood hemoglobin of all animals was 
monitored weekly following injection of BA and animals that did not develop 
anemia (Hb > 11g/dL, 7 days after injection of BA) were excluded from analysis. 
All animal studies were carried out in accordance with protocols approved by the 
Institutional Animal Care and Use Committee, Laboratory Animal Services at the 
Children’s Hospital of Philadelphia. 
 
Mouse sacrifice and tissue harvest 
Mice were anaesthetized using isoflurane and euthanized by cervical dislocation. 
A midline incision on the ventral side was used to expose the internal organs 
including the spleen, which was harvested. The femur and tibia of one leg were 
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also harvested and all organs were stored temporarily on ice in a solution of 1% 
PBS BSA (buffer). The femur and tibia were cut on both ends and a 26G X ½ 
needle connected to a 5 mL syringe was used to aspirate the bones with 5 mL of 
buffer to collect BM cells. The spleen was crushed between two glass slides to 
break down the outer membrane and a similar 26G ½ needle connected to a 5 
mL syringe was used to break down cellular aggregates in 5 mL of buffer. 
Harvested BM and spleen cells were then passed through a 40 micron filter and 
subsequently used for flow cytometric staining. 
 
Collection of serum and blood for CBC 
To prepare serum, 750 uL of blood was withdrawn retro-orbitally with a non-
heparinized capillary tube from anesthetized animals immediately prior to 
euthanasia. The blood was collected and stored at room temperature for 2 hours,  
and then centrifuged at 3000 rpm for 30 minutes. The supernatant (serum) was 
collected and stored at -80oC for further analysis 
For CBC, 40 uL of blood was withdrawn retro orbitally with a heparinized capillary 
tube from anesthetized animals and analyzed for CBC by the Advia 120 
Hematology system. 
 
Flow cytometric analysis 
To evaluate erythropoiesis, 106 cells of the BM and the spleen were aliquoted 
and washed with 1% PBS BSA (centrifugation at 300 g for 5 minutes). After 
discarding the supernatant, the cells were stained with TER119 APC, CD71 FITC 
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and CD44 PE at a dilution of 0.5 uL of the antibody suspended in 100 uL of 
staining buffer (1% PBS BSA). After 30 minutes of incubation on ice in the dark, 
cells were washed and re-suspended in 200 uL of staining buffer for analysis by 
flow cytometry. Cells were sorted using a BD FACS Calibur and results were 
analyzed on FloJo software (TreeStar). 
To examine mitochondrial superoxide production in erythroid progenitors, cells 
were stained with TER119 APC, CD29 FITC as described, and washed with PBS 
only. Following wash, cells were incubated with Mitosox Red (Life Technologies, 
Thermo Fischer Scientific) at a concentration of 5 µM for 15 minutes at 37oC in 
the dark and sorted using a BD FACS Calibur. 
For examining ROS in erythroid progenitors, cells were stained with TER119 
APC, CD29 FITC as described, and washed with PBS only. Following wash, cells 
were incubated with CM-H2DCFDA (Life Technologies, Thermo Fischer 
Scientific) at a concentration of 25 nM for 15 minutes at 37oC in the dark and 
sorted using a BD FACS Calibur. 
 
RBC Lifespan experiment 
0.875 mg of Sulfo-NHS-Biotin (Thermo Fischer Scientific) was dissolved in 200 
uL of PBS and injected intravenously in each mouse. 12 hours following injection 
of Biotin, peripheral blood collected from the mouse tail was stained with 
streptavidin PE, and PE fluorescence was analyzed by flow cytometry as a 
measure of biotinylated RBC. 24 hours following injection of Biotin the mice were 
injected with BA as described. 4, 7, 11 and 14 days following injection of BA, 
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peripheral blood collected from the mouse tail was stained with streptavidin PE 
and PE fluorescence was analyzed by flow cytometry as a measure of 
biotinylated RBC. 
 
Oxyblot 
Whole bone marrow and spleen cells were washed with 1% PBS BSA. Following 
centrifugation at 300 g for 5 minutes, supernatant was discarded and cell pellets 
were stored at -80C. Frozen cell pellets were treated with RIPA buffer for 
extraction of cell lysate proteins. Subsequently they were subjected to 
derivatization reaction with 2,4, dinitrophenyl hydrazine and oxidized proteins 
were detected with an anti-dinitrophenyl hydrazine antibody (Oxyblot protein 
oxidation detection kit-EMD Millipore) as described by Marinkovic et al. 
 
Iron Dextran experiment 
24 hours prior to injection of BA, mice were injected IP with iron dextran (Sigma 
Aldrich) at 1 gram/kg body weight of each mouse. 6 days following injection of 
BA mice were injected with a second dose of iron dextran and sacrificed 14 days 
following injection of BA. Sacrificed animals were analyzed for erythropoiesis and 
ROS production as described previously. 
 
Serum Iron and transferrin saturation experiment 
Iron parameters in the serum were tested as described by Gardenghi et al (273) 
using a diagnostic iron TIBC (total iron binding content) kit from Pointe Scientific. 
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Cytokine analysis 
Serum cytokines were measured by the Biolegend Legendplex, a bead based 
sandwich immunoassay, following instructions on the assay kit (Bioelgend). 
 
Statistics 
The data is presented as mean ± SD (standard deviation). An unpaired 2-tailed 
Student t test was used to assess significance (for comparison of two groups of 
samples with normal distribution by Shapiro Wilk’s normality test). Graphpad 
prism 7 and Microsoft Excel for Mac 2016 software was used. P < 0.05 was 
considered statistically significant.  
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Chapter 4 
Discussion and Future Perspectives 
 
The etiology of anemia in the context of inflammation, particularly one 
caused by pathogenic infections, is such that providing iron administration to 
ameliorate anemia in clinical settings is detrimental to disease prognosis and 
patient recovery. This warrants the need to examine cellular responses and 
molecular mechanisms underlying AI. Thus, the study of AI requires well 
established mammalian systems capable of simulating both the anemia and the 
inflammatory reaction seen in clinical settings. The BA model not only shows 
hallmarks of an inflammatory reaction, but also simultaneously induces 
significant anemia (in contrast to LPS or CFA models), and hence is being used 
as an ideal murine model to study AI.  
The first phase of response to BA in terms of cytokine upregulation, 
change in iron parameters, and impaired BM erythropoiesis in WT animals has 
been characterized in literature by others as well as by us. However, in this 
study, we were able to identify and characterize a second phase of response to 
BA. Like the first phase, the second phase is marked by an upregulation of 
cytokines. However, unlike the first phase, the second phase highlights a 
protective effect of lack of IL6 and a concurrent detrimental effect of iron 
overload. This divergence of BM erythroid recovery in the second phase 
	 58	
prompted us to investigate cellular responses impeding BM erythropoiesis. We 
found that upregulated ROS in BM erythroid progenitors positively correlates with 
impaired BM erythropoiesis and that this can be aggravated by iron overload. 
Moreover, in our studies we found that while absence of IL6 is protective, high 
levels of iron can impair BM erythropoiesis in the same animals. Our study not 
only elucidates altered mitochondrial ROS production in response to BA, but also 
highlights a ROS mediated deleterious effect on BM erythropoiesis by conditions 
of iron overload under AI. 
We noticed an upregulation of ROS under stress erythropoiesis in WT 
mice. We also showed that upregulation of ROS is a by-product of stress 
erythropoiesis induced by phlebotomy. However, as WT animals do not show the 
same improvement in BM erythropoiesis as IL6-KO mice, we postulated that 
increased ROS levels mediated by stress erythropoiesis + inflammation limits or 
slows down erythroid recovery. Iron not bound to transferrin has been previously 
linked to oxidative stress. Additionally, the potential presence of NTBI/LPI in WT 
animals, during the second phase, could also affect negatively erythropoiesis in 
presence of inflammation. To test the role of NTBI, we are currently studying the 
presence of a labile iron pool in mice with impaired erythroid recovery under AI.  
Moreover, it will also be worthwhile to investigate the presence of acute 
phase-reactant proteins such as Ferritin in the serum that are capable of binding 
to NTBI and potentially contributing to oxidative damage. Furthermore, it is 
possible that certain iron transporters such as Zip8, that import NTBI into 
erythroid progenitors in the BM might be upregulated under AI, allowing 
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excessive non-transferrin linked iron to impair differentiation of erythroid 
progenitors in the BM. In line with this theory, we would also like to test whether 
metal ion transporters such as Zip8 or Zip14 are upregulated in erythroid cells of 
mice that exhibit impaired erythroid recovery. 
Although NTBI can potentially impede BM erythropoiesis in the WT mice 
under AI, our results with the IL6-KO mice suggest that there might be an NTBI 
independent negative influence of the presence of this cytokine in BM 
erythropoiesis under AI. There are multiple studies showing increased NFkB 
promoter activation and IL6 production linked to upregulated ROS in murine 
skeletal muscle cells but whether this relationship extends to other cell types 
remains to be seen (209, 210, 211, 212). However, this evidence combined with 
our results that ROS is not upregulated in the absence of IL6 strengthens the 
idea that the link between IL6 and BM erythropoiesis might lie within ROS itself. 
How the mitochondrial generation of ROS impinges on the STAT3 dependent 
pathway downstream of the IL6 receptor or vice versa, still remains unknown.  
Our work shows a positive correlation between upregulation of ROS and a 
decline of BM erythroid differentiation. Given that we did not detect an activation 
of apoptosis in our ROS upregulated cells (not shown), our negative data point to 
the possible role of non-apoptotic forms of programmed cell death downstream of 
ROS upregulation, such as necroptosis. This idea is supported by the 
upregulation of the cytokine TNFa in both of our phases of response to BA, as 
this cytokine has been implicated as a key mediator of necroptosis, and derives 
its name from the process (142, 143, 144, 145, 146). Furthermore, in the past 
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decade there has been substantial work linking TNFa to ROS upregulation, 
although the evidence supporting the role of NFkB in this crosstalk between the 
two remains contradictory (135). Given the obvious role of TNFa in necroptosis 
and some literature suggesting it’s connection to ROS, we can speculate that 
upregulation of TNFa in combination with inflammation, ROS and excess of NTBI 
could trigger necroptosis and inhibit terminal erythroid differentiation in the BM. 
To test a potential role of necroptosis in AI, we are currently investigating 
recovery from BA in RIP3K KO mice that are resistant to necroptosis. Moreover, 
to further elucidate lineage specific impact of the absence of IL6 in protecting BM 
erythropoiesis under AI, we are crossing IL6 receptor (gp80) floxed mice with 
Epo R Cre and Vav Cre animals. 
From a clinical point of view, current treatments for AI include 
erythropoiesis stimulating agents in combination with oral or intravenous iron 
administration. IL6 blocking antibodies such as Tocilizumab have also been 
used. However, iron supplementation in the context of AI under active infections 
can potentially prevent pathogen clearance and disease prognosis. While 
blocking IL6 is effective, use of this also precludes any supportive functions of 
this cytokine in resolving inflammation. There is a need to parse out the 
independent contributions of this cytokine in anemia and in inflammation, to 
target specific IL6 mediated cellular responses for treatment of anemia without 
affecting its function as a primary responder under inflammation. Our results 
provide clues to intracellular responses that can be targeted for these purposes. 
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To summarize, our study identifies the presence of a second phase of 
response to BA, and characterizes this phase in terms of recovery in the absence 
of IL6 and in the presence of iron overloading conditions. Additionally, our study 
also detects ROS as a cellular response accompanying impaired erythroid 
recovery and suggests the potential of iron not bound to transferrin in damaging 
BM erythropoiesis.  
AI is a hallmark of numerous chronic inflammatory conditions and affects a 
large number of individuals. Production of inflammatory cytokines and anemia 
are also particularly acute in conditions such as sepsis, and this combination is 
often lethal. Therefore, there is a need to investigate underlying pathways 
contributing to the resulting anemia. Our study could potentially provide evidence 
of cellular responses that can be targeted in conditions of dysregulated iron 
metabolism for therapeutic benefits.  
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